The introduction of similar medicines to the original product may provide an opportunity for greater access to therapies for patients, but may raise many important questions especially on safety and effective therapies as well as on the relationship doctor – patient.

Please find further information here:

• European Medicinal Agency: www.emea.europa.eu
  
  
• Dr. Mikhail “Biosimilar Epoetins: A future in Europe”
  
  
• IAPO: Briefing paper on Biosimilar Medicines - http://www.patientsorganizations.org/showarticle.pl?id=727&n=37120
  
  
• CEAPIR statements: 28.02.2005, 31.10.2005

1. Biosimilars
2. Dr. Mikhail biosimilars in Europe
3. IAPO Biosimilars Briefing Paper Order Form
4. CEAPIR statement Feb. 2005.pdf
5. CEAPIR statement Oct. 2005.pdf